Gin Hwa Biotech, Inc.
TTPEX:780655.00
TWD
-0.50
(-0.90%)
ISIN
TW0007806002
Return %
Stock
S&P 500
1Y
-6.55
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Chun Hung Chen
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Kaohsiung City Taiwan
- IPO Date
- Dec 12, 2024
- Website
- gin-hwa.com
- Similar Companies
- Business
- Gin Hwa Biotech, Inc. is a Taiwan-based contract development and manufacturing organization (CDMO) and biotechnology company engaged in the research, development, formulation, and commercial production of functional health foods, nutritional supplements, and botanical health products. The company operates across comprehensive dietary supplement manufacturing and product lifecycle management segments, offering one-stop development solutions ranging from raw ingredient selection to finished-product delivery. Gin Hwa Biotech provides full-dosage contract manufacturing and original design services, encompassing softgel encapsulation; hard capsule filling; tableting; dry powder blending and sachet packaging; oral liquids, ampoules, and dual-chamber beverage packaging; concentrated botanical pastes; and functional jelly pouches. Its service portfolio comprises customized nutritional formulation development backed by a proprietary repository of more than 1,000 active formulations; standardized traditional Chinese herbal medicine extraction and concentration; product stability and pilot-scale batch testing; packaging engineering; regulatory compliance consultation; and quality assurance testing adhering to ISO 22000, HACCP, FSSC 22000, Halal, and U.S. FDA facility standards. The company primarily serves domestic and international nutraceutical brand owners, retail health chains, direct-selling enterprises, and pharmaceutical distributors. In recent corporate developments, Gin Hwa Biotech registered on the Taipei Exchange Emerging Stock Board in December 2024 and initiated preparations for its formal TPEx mainboard listing in October 2026, supported by a 3-million-share cash capital increase. To address expanding customer demand, the company is advancing the construction of its second manufacturing facility in Kaohsiung, which is scheduled for completion and operational commissioning in the first quarter of 2027 to double aggregate production capacity. Furthermore, the company established dedicated international business development divisions to accelerate market penetration across Southeast Asia and Europe, expanding beyond its primary Taiwan market base. Gin Hwa Biotech, Inc. was founded on November 28, 2019, and is headquartered in Kaohsiung City, Taiwan.